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Abstract
Aims Cardiac repair has steered clinical attention and remains an unmet need, because available regenerative therapies lack
robust mechanistic evidence. Pressure-controlled intermittent coronary sinus occlusion (PICSO), known to induce angiogenetic
and vasoactive molecules as well as to reduce regional ischemia, may activate endogenous regenerative processes in failing
myocardium. We aimed to investigate the effects of PICSO in patients with advanced heart failure undergoing cardiac
resynchronization therapy.
Methods and results Eight out of 32 patients were treated with PICSO, and the remainder served as controls. After elec-
trode testing including left ventricular leads, PICSO was performed for 20 min. To test immediate molecular responses, in both
patient groups, coronary venous blood samples were taken at baseline and after 20 min, the time required for the interven-
tion. Sera were tested for microRNAs and growth factors. To test the ability of up-regulated soluble factors on cell proliferation
and expression of transcription factors [e.g. Krüppel-like factor 4 (KLF-4)], sera were co-cultured with human cardiomyocytes
and ﬁbroblasts. As compared with controls, signiﬁcant differential expression (differences between pre-values and post-values
in relation to both patient cohorts) of microRNA patterns associated with cardiac development was observed with PICSO. Im-
portantly, miR-143 (P < 0.048) and miR-145 (P < 0,047) increased, both targeting a network of transcription factors (including
KLF-4) that promote differentiation and repress proliferation of vascular smooth muscle cells. Additionally, an increase of miR-
19b (P < 0.019) known to alleviate endothelial cell apoptosis was found, whereas disadvantageous miR-320b (P < 0.023) sus-
pect to impair expression of c-myc, normally provoking cell cycle re-entry in post-mitotic myocytes and miR-25 (P < 0.023),
decreased, a target of anti-miR application to improve contractility in the failing heart. Co-cultured post-PICSO sera signiﬁ-
cantly increased cellular proliferation both in ﬁbroblasts (P < 0.001) and adult cardiomycytes (P < 0.004) sampled from a
transplant recipient as compared with controls. Adult cardiomyocytes showed a seven-fold increase of the transcription factor
KLF-4 protein when co-cultured with treated sera as compared with controls.
Conclusions Here, we show for the ﬁrst time that PICSO, a trans-coronary sinus catheter intervention, is associated with an
increase in morphogens secreted into cardiac veins, normally present during cardiac development, and a signiﬁcant induction
of cell proliferation. Present ﬁndings support the notion that epigenetic modiﬁcations, that is, haemodynamic stimuli on ve-
nous vascular cells, may reverse myocardial deterioration. Further investigations are needed to decipher the maze of complex
interacting molecular pathways in failing myocardium and the potential role of PICSO to reinitiate developmental processes to
prevent further myocardial decay eventually reaching clinical signiﬁcance.
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Introduction
Chronic heart failure accounts for a substantial amount of
morbidity and mortality worldwide.1 Although not yet an
established therapy, structural myocardial regeneration may
beneﬁt an enormous population.2 Pressure-controlled inter-
mittent coronary sinus occlusion (PICSO), a trans-coronary si-
nus catheter intervention, was primarily developed to salvage
jeopardized myocardium during acute ischemic syndromes. It
has been shown that PICSO intervention leads to the activa-
tion of important growth factors such as vascular endothelial
growth factor and interleukin 6, which in turn may stimulate
cardiac regeneration via cardiomyocyte proliferation.3 Re-
cently, a report on PICSO in acute heart failure patients sug-
gests recovery beyond myocardial salvage.4 We
hypothesized that PICSO with its periodic ventricularization
of the coronary venous compartment may modify the con-
centration of molecules relevant to commence developmen-
tal pathways.
Aims
We aimed to investigate the effects of PICSO on the release
of soluble molecules linked to myocardial development
through direct comparisons among pre-intervention and
post-intervention sera and equivalent control sera. Further-
more, we aimed to investigate the effects of released mole-
cules on cellular events.
Methods
Study population
Patients with advanced heart failure undergoing cardiac
resynchronization therapy (CRT) implantation and older
than 18 years of age were eligible for this study. Exclusion
criteria included the presence of prosthetic heart valves or
indication for valve replacement, unstable angina pectoris,
known bleeding disorder, chronic steroid therapy, cancer, in-
fectious diseases of any cause, pregnancy, and haemody-
namic or electrical instability. All subjects provided written
informed consent. The study protocol and all procedures in-
volved complied with the Declaration of Helsinki and were
approved by the Ethics Committee of the Medical Univer-
sity of Vienna.
Study protocol
The study took place in the electrophysiology operating
suite during CRT device implantation. After left ventricular
electrode placement within the coronary veins and electri-
cal threshold testing, a specially designed coronary sinus
catheter with a curved tip and a helium inﬂatable balloon
was used for the application of PICSO (Contract Medical In-
ternational, Dresden, Germany). Periodic coronary sinus
pressure (CSP) elevation was achieved using an automated
PICSO controller (ARC Seibersdorf Research GmbH,
Seibersdorf, Austria).
Analysis of the collected sera
To investigate the effects of PICSO on the release of soluble
factors, coronary sinus blood samples before and after
20 min of treatment or the respective time in control patients
were taken. Samples were then centrifuged and shock frozen
for storage at 80°C. MicroRNA and proteomics analyses
were performed subsequently. As shown in Figure 1, sera
from coronary sinus blood were co-cultured with a mixture
of human ﬁbroblasts and adult cardiomyocytes stemming
from the septum of a failing heart from a patient undergoing
heart transplantation and commercially available human
ﬁbroblasts.
Statistical analysis
Statistical analyses were performed using SPSS for Win-
dows V20 (SPSS Inc., Chicago, IL, USA). The measure-
ments are expressed as mean ± standard deviation.
Preoperative patients’ characteristics were compared using
χ2 tests; in terms of n < 5 in one group, the Fisher’s ex-
act test was performed. An alpha error below P = 0.05




Thirty-two patients after successful CRT implantation were in-
cluded in the study. Eight patients were investigated with
PICSO for 20 min, and 24 patients constituted the control
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Figure 1 Study protocol and serum collection. (A) After advancement of a coronary sinus catheter and temporary pressure-controlled occlusion
(PICSO) of a major portion of outﬂow from coronary veins, pressures are increased as seen in (B); systolic pressures peaks are thought to be the driving
force to activate venous endothelium. (C) Immediately frozen to 80°, (D) human ﬁbroblasts and cardiomyocytes are co-cultured with patient sera to
estimate the proliferative power of each serum. After primary culture, cells underwent a starving period before co-cultured with patient serum.
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group. Between the two groups, no signiﬁcant differences
were noted at baseline.
Demographics and clinical data
Table 1 depicts demographics and clinical data, showing com-
parable parameter in both groups.
Parameters during the intervention
In PICSO patients, the mean CSP before the intervention
was 11.7 and 12.1 mmHg after the intervention.
During the intervention, CSP systolic pressures rose
107% to mean 24.2 mmHg CSP with systolic peaks of
52 mmHg.
Table 1 summary of demographics and clinical data
PICSO (n = 8) Control (n = 24) P-value (χ2 and Fisher’s exact testb)
Demographics
Age (years) ± SD (n) 73.25 ± 10.78 64.75 ± 11.0 0.076a
Gender (N and % male) 7 17 0.346
87.5% 70.83%
Ejection fraction (%) 23.13 ± 6.94 25.70 ± 8.20 0.433a
Clinical history
Diabetes 2 6 1
25% 25%
COPD 1 7 0.642
12.5% 29.17%
Hyperlipidaemia 6 17 1
75% 70.83%
Hypertension 8 20 0.217
100% 83.33%
Smoking 3 6 0.654
37.5% 25%
Previous stroke 1 1 0.444
12.5% 4.17%
Previous myocardial infarction 3 12 0.691
37.5% 50%
Valvular disease 3 10 1
37.5% 41.67%
Chronic atrial ﬁbrillation (anamnesis) 1 10 0.209
12.5% 41.67%
Atrial ﬁbrillation at admission 0 4 0.550
0% 16.67%
Dilated CMP 5 9 0.217
62.5% 37.5%
Ischaemic CMP 3 14 0.423
37.5% 58.33%
Valvular CMP 0 1 1
0% 4.17%
Conduction abnormalities
Left bundle branch block 5 17 0.66
62.5% 70.83%
Right bundle branch block 0 3 0.555
0% 12.5%
AV block 0 4 0.550
0% 16.67%
Medications
Beta-blocker 8 20 0.217
100% 83.33%
ARB or ACE inhibitor 8 21 0.294
100% 87.5%
Diuretic 8 20 0.217
100% 83.33%
Lipid-lowering agent 5 12 0.539
62.5% 50%
Device
CRT-D 4 18 0.218
CRT-P 4 6
ARB, angiotensin receptor blocker; ACE, angiotensin-converting enzyme; AV, atrioventricular; CMP, cardiomyopathy; COPD, chronic ob-
structive pulmonary disease; CRT-D, cardiac resynchronization therapy deﬁbrillator; CRT-P, cardiac resynchronization therapy pacemaker;
PISCO, pressure-controlled intermittent coronary sinus occlusion; SD, standard deviation.
aEvaluated using the unpaired Student’s t-test.
bFisher analysis was used if n < 5.
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Effects of pressure-controlled intermittent
coronary sinus occlusion on soluble factors
secreted into cardiac veins
MicroRNA
The time courses of microRNA in both groups were moni-
tored revealing distinguished trends. This difference (as re-
ported by the comparison of the difference normalized Ct
post-value minus normalized Ct baseline) was statistically
signiﬁcant for 16 of the tested microRNAs (Figure 2). In
the PICSO group, we observed a relative increase of
miR-19b, miR-101, miR-143, miR-144, and miR-145. A gene
enrichment analysis of the data emphasized possible candi-
date pathways to belong to the Wnt pathway (miR-101 and
miR-144), muscle organ development (miR-101 and miR-
144) or muscle (miR-143), aortic and coronary endothelial
function (miR-144), and muscle contraction (miR-19b). In
parallel, the concentrations of let-7b, miR-25, miR-191,
miR-320b, miR-421, and miR-486-5p were relatively
reduced.
In the control group with resynchronization only, miR-421,
let-7b, miR-485-5p, miR-25, miR-191, miR-30d, miR-584, and
miR-320b were increased, and miR-19b, miR-144, miR-143,
miR-101, miR-145, miR-107, and miR-363 were decreased.
Thus, these data suggest that PICSO treatment had several
signiﬁcant effects on the circulating plasma microRNA in
comparison with the control group.
Clinical observation and the mechanotransduction effect
induced by PICSO intervention indicate a domain change
between epigenetic forces and genome, a transition of hemo-
dynamic impulses into a pleiotropic molecular signalling pulse
as suggested by signiﬁcant changes in coronary sinus plasma
levels of several microRNAs. Regulation of cardiogenic gene
expression by microRNA has been shown to play a prominent
role in heart development. Recent data have identiﬁed vari-
ous microRNAs as critical regulators of the proper differenti-
ation, proliferation, and survival of cardiomyocytes,
endocardial cells, epicardial cells, and neural crest cells. The
potential of inﬂuencing microRNA expression may therefore
be utilized in management and prevention of cardiovascular
diseases.5
A number of studies demonstrated that elevated levels of
miR-143 and miR-145 play an important role in regulating
several transcription factors like octamer-binding transcrip-
tion factor 4, sex-determining region Y-box 2, and Krüppel-
like factor 4 (KLF-4) as well as promoting differentiation
and simultaneously repressing proliferation of vascular
smooth muscle cells. The signiﬁcant increase in plasma
levels of miR-143 and miR-145 in PICSO-treated patients to-
gether with the signiﬁcant up-regulation of KLF-4 is sugges-
tive of activation of such pathways. There are also a series
of other differentially up-regulated microRNA inﬂuencing
microRNA.
Whereas let-7b, let-7g, and miR-30d have been found in
some studies to be involved in epithelial mesenchymal trans-
formation and angiogenesis as well as improvement of con-
tractility and are therefore considered positive in
regenerative molecular pathways; in our patient series, the
Figure 2 Differentially expressed microRNA (miRNA). Here, we show differentially expressed miRNA for both groups. Delta differences between ﬁrst
and second serum collection are shown as mean ddCP for both groups. After normalization of data to global mean, a delta Cq value is obtained (dCq).
Differences in expression levels are calculated as dCq (1)  dCq (2) = ddCq. Only statistically signiﬁcant patterns of miRNA expression are shown.
miRNA 145 is involved in a double negative feedback loop with Krüppel-like factor 4 inducing lineage restricted differentiation. PICSO, pressure-con-
trolled intermittent coronary sinus occlusion.
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Table 2 Transcription factors in cardiac venous blood
Pre-values Post-values
Type Group Mean SD Mean SD P-value Change in %
39 kDa FGF5 PICSO 1590.06 767.70 1720.25 1195.02 0.3461 108.19
39 kDa FGF5 Control 5355.90 3002.89 5141.62 2637.02 0.2887 96.00
36 kDa FGF5 PICSO 2280.27 2214.61 2943.83 3000.44 0.2191 129.10
36 kDa FGF5 Control 3521.64 2600.49 2765.38 2449.93 0.1312 78.53
35 kDa FGF5 PICSO 4939.24 2099.17 5428.65 1682.89 0.1843 109.91
35 kDa FGF5 Control 4395.15 972.55 4987.40 1195.45 0.0858 113.48
33 kDa FGF5 PICSO 420.00 387.83 408.00 377.30 0.4518 97.14
33 kDa FGF5 Control 760.04 316.19 724.87 293.82 0.3898 95.37
60 kDa TBX5 PICSO 1765.94 863.50 1312.97 1055.07 0.0199 74.35 (P < 0.05)
60 kDa TBX5 Control 3923.35 2434.77 3420.49 2564.07 0.0392 87.18 (P < 0.05)
51 kDa TBX5 PICSO 15 583.03 9002.37 13 358.04 6304.52 0.1031 85.72
51 kDa TBX5 Control 18 691.01 3699.77 16 532.11 3648.23 0.0008 88.45 (P < 0.05)
41 kDa TBX5 PICSO 9052.13 7431.67 4229.24 4571.33 0.0343 46.72 (P < 0.05)
41 kDa TBX5 Control 8670.12 9768.61 4512.81 4529.47 0.0409 52.05 (P < 0.05)
48 kDa GATA4 PICSO 11 881.95 1853.15 9155.60 4549.00 0.2165 77.05
48 kDa GATA4 Control 20 211.56 8359.36 11 642.15 6247.43 0.0010 57.60 (P < 0.05)
52 kDa MEF2C PICSO 2022.00 783.74 2424.36 1290.11 0.1877 119.90
52 kDa MEF2C Control 2445.52 1038.12 2940.57 1197.48 0.0441 120.24 (P < 0.05)
49 kDa MEF2C PICSO 8211.22 1830.25 10 197.42 1832.86 0.0232 124.19 (P < 0.05)
49 kDa MEF2C Control 11 319.58 2698.46 11 750.39 3171.96 0.1896 103.81
39 kDa HAND2 PICSO 364.73 480.48 1041.79 555.15 0.1341 285.64
39 kDa HAND2 Control 936.69 664.02 1641.70 627.79 0.0336 175.27 (P < 0.05)
36 kDa HAND2 PICSO 1645.37 659.21 905.55 690.90 0.1317 55.04
36 kDa HAND2 Control 1285.81 800.58 796.52 442.24 0.0584 61.95
35 kDa HAND2 PICSO 2853.06 1721.25 2057.02 945.99 0.1313 72.10
35 kDa HAND2 Control 4247.16 864.58 3927.03 1265.71 0.1962 92.46
31 kDa HAND2 PICSO 11 503.93 3422.18 14 250.30 3086.66 0.1367 123.87
31 kDa HAND2 Control 9523.03 4450.82 13 858.94 4506.63 0.0032 145.53 (P < 0.05)
SD, standard diviation; PISCO, pressure-controlled intermittent coronary sinus occlusion.
Transcription factors sampled from coronary venous blood in relation to pre-interventional and post-interventional values in both groups
show a complex pattern of reactions in both groups. A potential interventional effect of PICSO can only be suspected in 49 kDa MEF2C. To
allow sophisticated interpretation, a larger cohort of patients is needed.
Figure 3 Krüppel-like factor 4 (KLF-4) in cardiomyocytes after serum exposure. Cardiomyocytes supravitally sampled from transplant recipient hearts
were exposed to serum collected in three control and three pressure-controlled intermittent coronary sinus occlusion (PICSO) patients according to
protocol. Pre-control and post-control were set as baseline ﬂuorescence intensity to compare signal differences in PICSO patients. Blue bar, 30 min;
red bar, 60 min; orange, 120 min after treatment start. Groups are indicated on the bottom. Bars indicate fold change to control group as deﬁned
as 1. Mean fold change is given above error bars of standard deviation. Signalling of sera co-cultured seem to peak at 60 min and decline thereafter.
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levels are lower in PICSO than in controls, requiring careful
interpretation in the context of multiple intertwined
processes and ambivalent responses of individual evoked
signals in context especially when induced in failing
myocardium.
Transcription factors
Several transcription factors sampled from coronary venous
blood reacted to the PICSO intervention and to lead testing
(Table 2), suggesting group difference especially in 49 kDa
MEF2C, a morphogen involved in cardiac morphogenesis,
the development of myogenesis and vasculature, and in-
crease in PICSO patients, whereas it remained unchanged in
controls. As seen in spite of the small number, pre-values
and post-values react in both groups to surgery and the inter-
vention, showing a complex matrix, which deserves larger
patient cohorts for meaningful interpretation. As reaction to
soluble factors released, KLF-4 was up-regulated in explanted
human myocardium from transplant recipients co-cultured
with post-PICSO sera based on protein levels (Figure 3).
Proliferation results
There was a signiﬁcant difference in the proliferation of
human ﬁbroblasts in the PICSO group compared with the
control group. The growth curve generated via real-time cell
analysis RTCA software revealed that ﬁbroblast growth
before and after PICSO-treated serum had distinctive trend
for cell proliferation proﬁle. Serum sample from after PICSO
treatment showed signiﬁcant increase in cell index immedi-
ately after sample addition. Results are depicted in (Figure 4).
Conclusions
The key element of our exploratory study is the association
of a temporary pressure increase in coronary veins leading
Figure 4 Real-time cell index for (A) human primary cardiomyocytes sampled from an explanted heart from a patient with heart failure during trans-
plantation and (B) commercially available ﬁbroblasts cultured in the presence of PICSO (n = 5 patients) or non-PICSO (n = 6 patients) sera from pre-
procedure and post-procedure. Cells index was measured up to 250 and 144 h for ﬁbroblast and primary cardiomyocytes, respectively. Student’s t-test
signiﬁcance is given in the graphs on the right for comparisons among groups at the end of the measurement periods. Note that post-PICSO sera
induced additional proliferation, whereas in post-control sera, no change was evident.
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to molecular changes known to be involved in cardiac
development. There appears to be a causative sequence
between the haemodynamic, ‘epigenetic’ impulse of
temporarily elevated coronary venous pressure via
mechanotransduction and the activation of coronary
venous vascular cells.6 As proposed in the ‘embryonic
recall hypothesis,’ this activation and subsequent
mechanotransduction via primary cilia and cytoskeleton of
venous endothelium induce a burst of a differential pattern
of microRNA in PICSO-treated patients together with the in-
duction of several transcription factors, as secreted mor-
phogens may be the key phenomenon that connects the
adult failing heart to innate but dormant cardiac develop-
mental pathways.7 The up-regulation of miR-143 in PICSO-
treated patients, as well as the ﬁndings by Miyasaka et al.
in the developing heart during the ﬁrst heartbeat, supports
our hypothesis in this context.8 In agreement to Marfella
et al., investigating soluble factors as prognostic biomarkers
in CRT patients, ﬂow-sensitive miRNA 145-5p increased
compared with controls in our verum group.9 Importantly,
the effects reported relate to secretion of molecules, rather
than de novo synthesis of morphogens, as the post-
procedure timing for assessment was limited to 20 min.
However, long-lasting signalling and the induction of a mo-
lecular cascade might lead via a domino effect to structural
regeneration.10
In summary, PICSO modulated the expression of several
relevant microRNA, which were detectable in blood of the
coronary sinus. The resulting microRNA pattern indicates a
situation favouring cardiac regeneration by action on
cardiomyocytes and cardiac ﬁbroblasts as well as by preven-
tion of stress-related antiangiogenetic effects.
Our observations also suggest that reconnecting adult fail-
ing hearts with cardiac development and therefore innate
dormant process can be revived and eventually may be used
to reverse the vicious cycle of severe symptoms in patients
with otherwise untreatable heart failure.
We postulate that application of PICSO in a controlled trial
in patients with severe chronic heart failure will substantiate
the clinical signiﬁcance of these molecular ﬁndings.
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